Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2019 · 10-Q
Revenue$157.00K$157.00K−98.3% vs Q2 2018 Net Income-$41.09M-$41.09MN/M vs Q2 2018 EPS Diluted-$0.07-$0.07N/M vs Q2 2018 Operating Income-$35,502,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$34,466,000N/M Margins · derivedOperating margin-22612.7%−22293.2 pt vs Q2 2018
Net margin-26170.1%−25684.9 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 1, 2019 · 32 d after period end